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Objectives. This study sought to determine whether patients 
who are homozygous for the deletion (D)-type alMe of the angioten- 
sin-converting enzyme gene display augmented ventricular dila- 
tion after myocardial infarction. 
Background. Recent evidence suggests that the deletion-type 
allele of the angiotensin-converting enzyme gene (DD genotype) is 
associated with an increased prevalence of myocardial infarction 
and myocardial hypertrophy. However, it is unknown whether the 
DD genotype is associated with adverse cardiac remodeling. To 
address this question we determined the genotype in patients 
enrolled in the Captopril and Thrombolysis Study (CATS), a 
prospective trial in which patients received either captopril or 
placebo during and after thrombolysis for a first anterior myo- 
cardial infarction. 
Methods. Cardiac volume was determined by echocardiography 
immediately after thrombolysis and at 1-year follow-up. The 
genotype for the angiotensin-converting enzyme was determined 
in 96 patients. Norepinephrine levels were assessed uring and 
immediately after thrombolysis. 
Results. Immediately after thrombolysis, cardiac volume did 
not differ between genotype groups. However, at 1-year follow-up, 
both end-systolic and end-diastolic left ventricular volumes were 
significantly greater in the DD-genotype group. Norepinephrine 
increased to higher levels in the DD-genotype group that received 
placebo therapy. Captopril treatment effectively blunted both the 
norepinephrine increase and cardiac dilation in the DD-genotype 
group. 
Conclusions. This exploratory study suggests that homozygosity 
for the angiotensin-converting enzyme deletion-type allele is as- 
sociated with augmented neurohumoral activation as well as 
augmented cardiac dilation after an acute anterior myocardial 
infarction, an effect that may be susceptible to angiotensin- 
converting enzyme inhibition. 
(JAm Coll Cardiol 1995;25:1622-6) 
The activity of the angiotensin-converting e zyme may be an 
important modulator of cardiac growth and remodeling. In 
particular, recent findings (1,2) suggest that angiotensin- 
converting enzyme activity and messenger ribonucleic acid 
expression are induced after myocardial infarction and 
during cardiac pressure overload. Furthermore, inhibition of 
angiotensin-converting enzyme reduces ventricular dilation 
after myocardial infarction (3). 
Genetic background may contribute to the activity of 
angiotensin-converting enzyme. An insertion/deletion poly- 
morphism in the human angiotensin-converting e zyme gene 
has been described in which subjects who are homozygous 
for the deletion allele (DD genotype) have higher levels of 
angiotensin-converting e zyme activity. Furthermore, the DD 
genotype has been associated with an increased prevalence of 
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myocardial infarction (4), left ventricular hypertrophy (5) and 
hypertrophic cardiomyopathy (6). 
However, it is not presently known whether the DD geno- 
type is associated with augmented cardiac dilation after myo- 
cardial infarction. We tested this hypothesis in patients en- 
rolled in the Captopril and Thrombolysis Study (CATS) (7), a 
multicenter p ospective clinical trial that investigated the effect 
of captopril versus placebo in patients after a first anterior 
myocardial infarction. 
Methods  
The CATS trial (7) is a double-blind, randomized, placebo- 
controlled study in patients with a first anterior myocardial 
infarction, treated with thrombolytic therapy (streptokinase 
intravenously). Two hundred ninety-eight patients were en- 
rolled in 10 hospitals in The Netherlands and were randomized 
to receive ither captopril (target dose 75 rag/day) or placebo. 
Immediately after completion of the streptokinase infusion, 
treatment was started and continued for 1 year. The primary 
objective of the trial was to assess the long-term effect of 
captopril on echocardiographic left ventricular volume. Echo- 
cardiographic determination f cardiac end-systolic and end- 
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Table 1. Volume Indexes (ml/m 2) in Three Separate Genotype Groups 
II-Genotype Group ID-Genotype Group DD-Genotype Group 
(n = 20) (n - 42) (n = 34) 
End-systolic index 
Baseline 23.9 _+ 4.4 23.5 + 1.2 24.1 _+ 1.5 
After 1 y~ 24.2 _+ 2.4 25.8 _+ 1.7 30.2 _+ 3.1 
End-diastolic index 
Baseline 54.9 _+ 2.8 52.9 _+ 2.1 53.1 _+ 2.2 
After 1 yr 54.9 _+ 3.4 59.2 _+ 2.3 62.3 _+ 3.7 
Analysis of variance with contrast demonstrated a significant linearity of the effect of the deletion allele on systolic 
volume after 1 year (p = 0.007) and on diastolic volume after I year (p = 0.013). Data presented are mean value _+ SEM. 
DD = genotype of homozygosity for the angiotensin-converting e zyme deletion allele; ID = genotype of one 
angiotensin-converting e zyme deletion allele and one angiotensin-converting e zyme insertion allele; lI = genotype of 
homozygosity for the angiotensin-converting e zyme insertion allele. 
diastolic volumes was performed in the apical four- and 
two-chamber views. Recordings were made directly after 
thrombolysis and 1 year after myocardial infarction. 
Blood samples were taken to determine the time course of 
alpha-hydroxybutyrate dehydrogenase release as a measure of 
infarct size according to a standard protocol. In addition, 
blood samples for determination f norepinephrine levels and 
angiotensin-converting e zyme activity were measured atbase- 
line (before thrombolysis) and 1, 12 and 24 h after throm- 
bolysis. 
In 96 patients, the genotype for the angiotensin-converting 
enzyme was determined after completion of echocardiographic 
follow-up by a method previously described in detail (5). All 
patients enrolled in the trial were asked to visit the clinic to 
have a blood sample taken for genotyping. The laboratory 
responsible for genotyping performed the determinations with- 
out knowledge of any clinical data. 
Statistical analysis. Patients were grouped with regard to 
genotype. Data for ventricular volumes are depicted in Table 1 
for each group. Because heterozygous patients did not signif- 
icantly differ from patients homozygous with respect o the 
insertion allele, data from these groups were pooled for 
analysis. 
Group differences were tested by analysis of variance in 
which echocardiographic volume data were corrected for in- 
farct size by adding the cumulative alpha-hydroxybutyrate 
dehydrogenase as a covariate. Baseline characteristics of the 
patients in which the genotype was determined were compa- 
rable to the overall study population. 
the heterozygous group (Table 1). Analysis of variance with 
contrast revealed linear effects of the deletion allele for both 
systolic (p = 0.007) and diastolic volumes (p = 0.013) after 
1 year. 
When the groups were subdivided by placebo or captopril 
treatment, only the placebo-treated DD-genotype group dis- 
played a significant increase in left ventricular end-systolic 
volume index; the increase in systolic volume in the captopril- 
treated DD-genotype group was not statistically significant 
(Table 3). 
The surge of norepinephrine levels after thrombolysis was 
similar or somewhat lower in the DD-genotype group than in 
the non-DD-genotype group (norepinephrine 1 h after throm- 
bolysis [mean __ SD] 797 + 71 pg/ml in the DI/II genotype 
group vs. 595 + 85 pg/ml in the DD-genotype group, p = NS). 
However, when the groups were subdivided by treatment, a 
different pattern was observed. In the DD-genotype group 
treated with placebo, the surge in norepinephrine was in- 
creased compared with that in the placebo-treated non-DD- 
genotype group (Fig. 2). In contrast, in the DD-genotype 
group who received captopril, the surge in norepinephrine 
levels was not significantly decreased compared with that in the 
captopril-treated non-DD-genotype group (norepinephrine 
1 h after thrombolysis, 779 _+ 181 pg/ml in the DD genotype 
group vs. 1,054 _+ 175 pg/ml in the DI/II-genotype group, p = 
NS). 
Finally, baseline angiotensin-converting e zyme activity was 
higher in the DD-genotype group (29 _+ 3 vs. 23 + 2 U/liter, 
p = 0.04). 
Resu l ts  
Baseline characteristics did not differ significantly between 
DD-genotype and non-DD-genotype groups, including enzy- 
matic infarct size and left ventricular volume (Table 2). A total 
of 45 patients received captopril (17 with the DD-genotype), 
and 51 received placebo (17 with the DD genotype). 
At 1-year follow-up, both end-systolic and end-diastolic 
volume indexes were significantly higher in the DD-genotype 
group (Fig. 1). Left ventricular volumes were intermediate in 
Discuss ion  
The present exploratory study suggests that ventricular 
dilation after anterior myocardial infarction is augmented in 
patients who are homozygous for the deletion-type allele of 
the angiotensin-converting e zyme gene. This seems to be 
sensitive to angiotensin-converting e zyme inhibition. Our 
study showed that the increase in ventricular volume was 
significant in the DD-genotype group treated with placebo 
but was no longer significant in those who received capto- 
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Table 2. Baseline Characteristics in Patients Homozygous for the Angiotensin-Converting Enzyme 
Deletion Alleles and in Patients With Genotypes Not Homozygous for Angiotensin-Converting 
Enzyme Deletion Alleles 
ID/II-Genotype Group DD-Genotype Group 
(n = 62) (n = 34) 
Mean age (yr) 59.1 _+ 9 58.3 -+ 9 
Gender (M/F) (%) 82/18 85/15 
Clinical history (%) 
Ischemic heart disease 8 3 
Hypertension 23 21 
Diabetes mellitus 5 15 
Current smoker 63 73 
Killip class (%) 
I 81 76 
II 18 24 
Concomitant medication at randomization (%) 
Beta-blockers 23 24 
Calcium-antagonists 15 9 
Diuretic drugs 10 3 
Nitrates 15 9 
Systolic blood pressure (ram Hg) 127 _+ 2 125 -+ 3 
Diastolic blood pressure (ram Hg) 75 _+ 1 77 -+ 2 
Total alpha-HBD 1,277 _+ 122 986 + 136 
End-systolic volume (ml/m 2) 23.6 _+ 1.1 24.1 + 1.5 
End-diastolic volume (ml/m 2) 53.7 _+ 1.7 53.1 -+ 2.2 
Data presented are mean value _+ SEM or number of patients. F = female; HBD = hydroxybutyrate d hydrogenase; 
M = male; other abbreviations as in Table 1. 
pril. The results cannot be explained by differences in infarct 
size because infarct size (as determined by total alpha- 
hydroxybutyrate d hydrogenase) was similar to or even 
smaller than that in the DD-genotype group. 
The mechanisms responsible for these findings cannot be 
Figure 1. End-systolic volume index (ESVI) and end-diastolic volume 
index (EDVI) in ml/m 2measured by echocardiography at baseline 
(after thrombolysis) and after 1 year. Both treatment groups are 
pooled. Results are mean value _+ SEM, and p values for the 
differences at1 year between the DD-genotype and II/DI-genotype 
groups are indicated, as obtained by analysis of variance. 
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directly derived from our data. However, neurohumoral f c- 
tors may be different in patients of the various angiotensin- 
converting enzyme genotype groups. First, plasma ngiotensin- 
converting enzyme activity may be increased in patients with 
the DD genotype, as has been previously described (8). The 
response to inhibition of the enzyme also seems to be altered 
in patients with the DD genotype: The normally occurring 
increase in angiotensin-converting enzyme activity during 
angiotensin-converting enzyme inhibition (upregulation) (9) 
seems to be enhanced inpatients with the DD genotype (10). 
The present data suggest that the norepinephrine surge on 
reperfusion was significantly higher in untreated patients 
with the DD genotype. This elevation was susceptible to 
angiotensin-converting enzyme inhibition because it did not 
occur in the DD-genotype group treated with captopril. Thus, 
neurohorrnonal activation after myocardial infarction may be 
amplified in patients with the DD genotype, thereby possibly 
leading to an adverse outcome. 
Other potential mechanisms should be considered as 
well, such as differences in blood pressure or patency of the 
reperfused arteries. The latter is suggested by the finding 
that the DD genotype is also associated with an increased 
prevalence of restenosis after coronary angioplasty during 
acute myocardial infarction (11). With regard to blood 
pressure, it is known that the DD genotype isnot associated 
with hypertension (12), and we also found no differences in
blood pressure. However, this finding does not preclude 
changes in blood pressure that may occur in these patients 
without leading to classic hypertension. 
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Table 3. Volume Indexes As Subdivided by Genotype and Treatment 
End-Systolic Volume Index 
(mean change ml/m 2 _+ SEM) 
End-Diastolic Volume Index 
(mean change ml/m 2 + SEM) 
tD/II-Genotype Group DD-Genotype Group ID/II-Genotype Group DD-Genotype Group 
Treatment (n = 39) (n = 18) (n = 39) (n = 18) 
Placebo (n = 28) 1.5 + 2.1 7.1 _+ 3* 2.9 _+ 3.4 7.6 _+ 4.9 
Captopril (n = 29) 2.3 _+ 2 3.1 _+ 3 4.5 _+ 3.3 6.7 _+ 4.9 
*p < 0.05, significant increase from baseline (95% confidence interval 0.2 to 14). Abbreviations a  in Table 1. 
Finally, we found that the effect of the angiotensin- 
converting enzyme insertion/deletion polymorphism on ven- 
tricular volumes after myocardial infarction is proportional to 
the number of deletion alleles present (either one or two). 
Such additive ffects, rather than an all-or-nothing phenome- 
non, further suggest hat this gene may serve as a disease 
modifier ather than as a direct causal agent. 
Study limitations. The present study was not designed to 
establish a causal role for a specific gene in postinfarction 
remodeling. Any association between a specific polymorphism 
and a particular phenotype may not be attributable tothe gene 
under investigation but rather to the region of the genome on 
which the gene is located. Further studies will be needed 
before the angiotensin-converting e zyme gene can be linked 
to dilation of the left ventricle after myocardial infarction. 
Furthermore, we studied asmall number of patients and, in 
particular, small treatment groups. Therefore, it should be 
emphasized that the results need further confirmation i larger 
studies. 
Figure 2. Plasma norepinephrine (pg/ml) as determined in samples 
taken before (first point) and after thrombolysis tarting 1 h after 
thrombolysis. Only placebo-treated patients are depicted. Results are 
mean value -+ SEM, and p values are obtained by analysis of variance. 
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Clinical implications. The present data suggest that in the 
future genetic markers may be of value in stratifying patients 
according to risk of developing ventricular dilation. The find- 
ing that augmented left ventricular dilation and increased 
norepinephrine levels were blunted by captopril therapy sug- 
gests a role for the angiotensin-converting e zyme gene in this 
process. Therefore, our study is in line with investigations that 
demonstrated the beneficial effects of angiotensin-converting 
enzyme inhibition on cardiac remodeling after myocardial 
infarction (3). However, our limited sample size does not allow 
us to draw conclusions with respect to the possible additional 
benefit that angiotensin-converting e zyme inhibition may 
have in patients with the DD genotype. 
Conclusions. Taken together, our data suggest hat ho- 
mozygosity for the angiotensin-converting e zyme deletion- 
type allele renders patients more susceptible for neurohumoral 
activation after an anterior myocardial infarction, which in turn 
may augment left ventricular dilation. 
We express our gratitude to Pieter-Jan de Kam, MSc for statistical analysis and 
to G/inter Riegger, MD for critical discussion of the manuscript. 
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